Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC-TMS
NCT07227103Phase 3Recruiting
- Sponsor
- NRx Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of d-cycloserine + lurasidone in treatment-resistant depression (TRD), sponsored by NRx Pharmaceuticals. Planned start Dec 2026; status: recruiting.
02
Drugs
d-cycloserine + lurasidone
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT07227103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227103.